CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
Somatropin (recombinant human growth hormone)drug
Likely dose
Somatropin (recombinant human growth hormone) 3.0mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00071240
NCT00071240Phase 2Completed

The Use of Recombinant Growth Hormone to Enhance T-Cell Production in Adults Infected With HIV-1

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Oct 17, 2003·Updated Aug 17, 2009

In Brief

A Phase 2 clinical trial evaluating Somatropin (recombinant human growth hormone) for HIV Infections. Completed, enrolled 22 participants across 1 site.

Detailed Summary

Growth hormone plays an important role in the development of the immune system. Studies suggest that growth hormone may promote growth of the thymus, a gland responsible for the production of important immune cells called T cells. Since these cells are lost during the course of HIV infection, it is possible that growth hormone treatment could help restore the immune system. This study will determine whether the administration of growth hormone can increase the size and function of the thymus and cause an increase in the number of new T cells in the blood of people infected with HIV. Study hypothesis: Growth hormone treatment will enhance T cell production in HIV infected adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 17, 2003
Enrollment StartOct 1, 2002
Primary CompletionSep 1, 2007
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 22.7 years ago

Interventions

Somatropin (recombinant human growth hormone)drug

3.0mg sc daily for 6 months, followed by 1.5mg sc daily for 6 months. Dose stopped, held or reduced by study investigators as indicated by adverse events